Related Experiment Video
Updated: Mar 31, 2026

Delivery of Cardioactive Therapeutics in a Porcine Myocardial Infarction Model
Published on: February 10, 2023
Current knowledge and recent development on management of peripartum cardiomyopathy
Nadia Bouabdallaoui1, Frederic Mouquet2, Guillaume Lebreton1
11 Cardio-Thoracic Surgery Department, Pitié-Salpétrière Hospital, France.
Abstract:
Heart failure with left ventricular dysfunction occurring during pregnancy or during the post-partum period in patients without history of cardiovascular disease defines peripartum cardiomyopathy (PPCM). PPCM carries a high morbidity and mortality rate as well as the possibility of recovery ad integrum. Its incidence shows ethnic variations, with a greater prevalence of the disease among women with African descent. Pathogenesis of PPCM remains poorly understood. Both "oxidative stress-prolactin axis" and "anti-angiogenic-signaling excess" hypotheses are currently being investigated. Novel diagnostic strategies and biomarkers are currently being evaluated. Besides conventional treatment of heart failure, targeted therapies such as pharmacological prolactin blockade are under evaluation. The aim of this short review is to highlight current management as targeted therapy has far been disappointing.
Related Concept Videos
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Pericarditis III: Medical Management
Cardiomyopathy VI: Nursing Management
Myocarditis III: Medical Management

